Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12391.1;5 PFLS-LS
• Titre du projet anglais: Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy.

Description succincte (Anglais)

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy

Résumé des résultats (Abstract) (Anglais)

Notch is a transmembrane receptor playing a key role in cancer. Previous work at EPFL in partnership with Debiopharm has led to the development of two bioassays to identify inhibitors of the Notch pathway. EPFL, Debiopharm & Atheris have completed a CTI funded project (10917.1 PFLS-LS) to screen selected libraries in the two bioassays resulting in the identification of several novel Notch pathway inhibitory peptides. This project aims to optimize and validate (in in vitro and animal models) these peptides for further pharmaceutical development.